Article
Gastroenterology & Hepatology
Jennifer M. Kolb, Mindy Chen, Anna Tavakkoli, Jazmyne Gallegos, Jack O'Hara, Wyatt Tarter, Camille J. Hochheimer, Bryan Golubski, Noa Kopplin, Lilly Hennessey, Anita Kalluri, Shalika Devireddy, Frank I. Scott, Gary W. Falk, Amit G. Singal, Ravy K. Vajravelu, Sachin Wani
Summary: Most EAC patients do not have a previous BE diagnosis, indicating a failure of current screening practices. Understanding patient attitudes and barriers is crucial for improving BE screening adherence.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2023)
Review
Pharmacology & Pharmacy
Max M. Puthenpura, Krishna O. Sanaka, Yi Qin, Prashanthi N. Thota
Summary: Barrett's esophagus (BE) is a precursor to esophageal adenocarcinoma (EAC), but the actual risk of EAC in non-dysplastic Barrett's esophagus (NDBE) is low. The main management approach is to control gastroesophageal reflux disease (GERD) and participate in surveillance programs. Surveillance methods include regular biopsies and biopsies of mucosal irregularities. Challenges in surveillance include missed diagnoses, non-compliance with guidelines, and lack of strong evidence. Emerging imaging techniques, artificial intelligence, and risk prediction models have the potential to improve surveillance methods.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE
(2022)
Article
Gastroenterology & Hepatology
Anouk Overwater, Sjoerd G. Elias, Erik J. Schoon, Jacques J. G. H. M. Bergman, Roos E. Pouw, Bas L. A. M. Weusten
Summary: This study aimed to describe the course of pain and dysphagia after radiofrequency ablation (RFA) treatment for Barrett's esophagus (BE) neoplasia and identify associated risk factors. The results showed that 95% of patients reported post-RFA pain, with 64% experiencing major pain. Dysphagia was present in 83% of patients.
Article
Multidisciplinary Sciences
Arvind J. Trindade, Jianying Zhang, Kara L. Raphael, Jiejing Qiu, John Hauschild, Petros C. Benias
Summary: This retrospective observational study examined the utilization of endoscopic ablation therapy and esophagectomy in patients with Barrett's esophagus. The study found an increasing trend in the utilization of ablation therapy, while esophagectomy showed a decreasing trend. These findings suggest that endoscopic ablation therapy has become the predominant method of treatment for Barrett's esophagus with dysplasia.
SCIENTIFIC REPORTS
(2022)
Review
Medicine, General & Internal
Samuel Jesus Martinez-Dominguez, Angel Lanas, Maria Jose Domper-Arnal
Summary: The main clinical relevance of Barrett's esophagus is its potential progression to esophageal adenocarcinoma. Screening is not recommended for the general population, but surveillance is needed after diagnosis of BE. The gold standard for diagnosis and surveillance is high-definition oral endoscopy with random biopsies. Visible lesions should be completely resected, and in the absence of visible lesions, radiofrequency ablation should be performed.
Article
Surgery
Mate Knabe, Jens Wetzka, Lukas Welsch, Johannes Richl, Florian Michael, Sandra Blosser, Myriam Heilani, Holger Kronsbein, Andrea May
Summary: This study aimed to compare the safety, effectiveness, and eradication rates of radiofrequency ablation (RFA) and hybrid argon plasma coagulation (H-APC) in eradicating Barrett's esophagus. The results showed that the H-APC group had slightly higher eradication rates, while the RFA group experienced significantly more severe and longer-lasting pain.
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
(2023)
Review
Gastroenterology & Hepatology
John J. McGoran, Krish Ragunath
Summary: Barrett's esophagus is a precursor to esophageal adenocarcinoma, and endoscopic surveillance followed by endoscopic eradication therapy is the current practice. The mantra of 'Detect-Resect-Ablate' guides the therapeutic approach, emphasizing the importance of high-quality endoscopy in identifying associated pathology and preventing dysplasia recurrence. The review discusses current practices, pitfalls, complications, and future perspectives in this field, with a focus on bridging clinical practice differences between Western and Asian nations.
DIGESTIVE ENDOSCOPY
(2021)
Article
Gastroenterology & Hepatology
Annieke W. Gotink, Yonne Peters, Marco J. Bruno, Peter D. Siersema, Arjun D. Koch
Summary: This study assessed the feasibility and safety of a new nonthermal device, the EndoRotor, as a first-line ablation technique for the eradication of Barrett's esophagus (BE). The results showed that using this device for endoscopic ablation of BE is technically demanding, with a longer procedure time and a high complication rate.
Article
Multidisciplinary Sciences
Carlijn A. M. Roumans, Manon C. W. Spaander, Iris Lansdorp-Vogelaar, Katharina Biermann, Marco J. Bruno, Ewout W. Steyerberg, Dimitris Rizopoulos
Summary: This study examines the value of using longitudinal evolutions of histological findings and immunohistochemical biomarkers to assess the risk of progression in Barrett's esophagus. The results show that the longitudinal evolutions of aberrant expression of p53 and SOX2 are associated with an increased risk of high-grade dysplasia/esophageal adenocarcinoma, and there is weak evidence of an association with the longitudinal evolution of the presence of LGD. The model performs well, with the ability to estimate the probability of biomarker aberrant expression based on multiple longitudinal observations for future BE patients.
Review
Biochemistry & Molecular Biology
Pelin Ergun, Sezgi Kipcak, Serhat Bor
Summary: Barrett's esophagus (BE) is a condition resulting from chronic gastroesophageal reflux disease, which may progress to esophageal adenocarcinoma (EAC). The histological dysplasia grade is commonly used as a biomarker, but its effectiveness is limited due to cost and lack of progression in many BE patients. Clinicians require multiple or more quantitative biomarkers for early diagnosis of EAC, which has high mortality. Epigenetic factors in the early stages of neoplastic transformation show promise as predictive biomarkers. This review summarizes current research on DNA methylations, histone modifications, and noncoding RNAs (miRNAs) during the progression from BE dysplasia to EAC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Surgery
Bashar Qumseya, Yazen Qumsiyeh, Ahmed Sarheed, Robyn Rosasco, Amira Qumseya
Summary: This study aimed to assess the effect of Roux-en-Y gastric bypass (RNY) on Barrett's esophagus (BE) in obese patients. The systematic review and meta-analysis of studies showed that a majority of patients with BE who underwent RNY had remission or improvement, while a significant minority showed no change on follow-up endoscopy.
Article
Gastroenterology & Hepatology
Quinn S. Solfisburg, Sarmed S. Sami, Joel Gabre, Ali Soroush, Lovekirat Dhaliwal, Claire Beveridge, Zhezhen Jin, John M. Poneros, Gary W. Falk, Gregory G. Ginsberg, Kenneth K. Wang, Charles J. Lightdale, Prasad G. Iyer, Julian A. Abrams
Summary: Recurrence of intestinal metaplasia at the gastroesophageal junction (GEJIM) after endoscopic eradication of Barrett's esophagus (BE) is common, but not associated with an increased risk of subsequent dysplasia. Older age and longer initial BE length are independently associated with recurrence.
GASTROINTESTINAL ENDOSCOPY
(2021)
Article
Evolutionary Biology
Lucian P. Smith, Jon A. Yamato, Patricia C. Galipeau, Thomas G. Paulson, Xiaohong Li, Carissa A. Sanchez, Brian J. Reid, Mary K. Kuhner
Summary: Barrett's Esophagus is a neoplastic condition that can progress to esophageal adenocarcinoma. Early steps in the formation of the Barrett's segment strongly influence whether patients will develop cancer in the future.
EVOLUTIONARY APPLICATIONS
(2021)
Review
Medicine, General & Internal
Francesco Maione, Alessia Chini, Rosa Maione, Michele Manigrasso, Alessandra Marello, Gianluca Cassese, Nicola Gennarelli, Marco Milone, Giovanni Domenico De Palma
Summary: Barrett's Esophagus is a common condition associated with chronic gastroesophageal reflux disease and has a higher risk of developing esophageal adenocarcinoma. Low and high-grade dysplasia precede neoplastic transformation in this condition. The evaluation of low-grade dysplastic esophageal mucosa is still controversial, but endoscopic surveillance and minimally invasive endoscopic treatments such as endoscopic mucosal resection and radiofrequency ablation are available options. Cryotherapy ablation and argon plasma coagulation are novel endoscopic treatments with high eradication rates and fewer complications and post-procedural pain.
Article
Gastroenterology & Hepatology
Cary C. Cotton, Nicholas J. Shaheen, Aaron P. Thrift
Summary: Endoscopic surveillance after successful ablation of baseline high-grade dysplasia or intramucosal cancer is much more effective than surveillance after successful treatment of baseline low-grade dysplasia in preventing invasive adenocarcinoma.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2022)